TEL
AVIV, Israel, March 29,
2023 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company
focused on the discovery and development of innovative therapeutics
for fibro-inflammatory diseases with high unmet need, today
announced the company will provide a Corporate Update on
Monday, April 17, 2023, at
8:00 am Eastern Time. This event
replaces the webcast and call originally scheduled for March 31, 2023.
During the event, Chemomab's management team will review recent
corporate developments and conduct a live question-and-answer
session.
A replay will be available on Chemomab's website for 90 days at
www.chemomab.com.
Live Webcast and Conference Call at 8:00 am Eastern Time, Monday, April 17, 2023
Click this Webcast link to access the live webcast or
replay.
The live webcast and replay can also be accessed at the News
& Events section of the Investors page on
the Chemomab website
at investors.chemomab.com/events.
Conference Call Access via Telephone
US Investors:
+1 (877) 407-9208
International Investors: +1 (201) 493-6784
Conference Passcode: #13735392
Or click on Call me™ for instant telephone access to the
event
Please call 5-10 minutes before the scheduled start time,
enter the conference passcode and ask the operator for the Chemomab
conference call.
About Chemomab Therapeutics
Chemomab is a clinical
stage biotechnology company focusing on the discovery and
development of innovative therapeutics for fibrotic and
inflammatory diseases with high unmet need. Based on the unique and
pivotal role of the soluble protein CCL24 in promoting fibrosis and
inflammation, Chemomab developed CM-101, a monoclonal antibody
designed to bind and block CCL24 activity. CM-101 has demonstrated
good tolerability along with the potential to treat multiple severe
and life-threatening fibrotic and inflammatory diseases.
Encouraging results from a Phase 2 liver fibrosis biomarker study
in NASH patients and an investigator study of CM-101 in COVID-19
patients with severe lung injury were recently reported, and a
Phase 2 trial in primary sclerosing cholangitis patients is
ongoing. Chemomab expects to open a Phase 2 systemic sclerosis
trial for patient enrollment around midyear of 2023. For more
information on Chemomab, visit chemomab.com.
Contacts:
Investor
Relations:
|
Investors &
Media:
|
Irina Koffler
|
Barbara
Lindheim
|
LifeSci Advisors,
LLC
|
Chemomab
Therapeutics
|
Phone: +1 (917)
734-7387
|
Consulting Vice
President
|
ir@chemomab.com
|
Investor & Public
Relations,
|
|
Strategic
Communications
|
|
barbara.lindheim@chemomab.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-provide-a-corporate-update-on-april-17-2023-301784348.html
SOURCE Chemomab Therapeutics, Ltd.